Skip to content
Search

Latest Stories

Sri Lanka eyes tougher import controls to halt forex crisis

Sri Lanka eyes tougher import controls to halt forex crisis

SRI LANKA'S central bank on Monday (28) called for further import restrictions to address a crippling foreign exchange crisis, following a string of loans from Asian neighbours including Bangladesh.

The island nation's foreign exchange reserves were badly hit last year amid the Covid-19 pandemic as the local currency came under intense pressure.


International rating agencies have since expressed fears that Colombo would not be able to service its huge foreign debt.

The Central Bank of Sri Lanka last week tightened its controls on dollar sales, leading commercial financial institutions to impose quotas on importers of essential commodities.

But central bank governor WD Lakshman said more restrictions were needed.

"What the central bank is doing now with the participation of all commercial banks, is judicious management of imports and foreign reserves," Lakshman said in a statement.

The bank was "of the view that there is further space to curtail non-essential and non-urgent imports," he added.

Sri Lanka had already banned luxury goods and car imports to combat the outflow of foreign currency.

The ban first imposed in March last year applied to turmeric, a staple in local curries as well as tiles, toilets, tyres, cosmetics, vehicle spare parts, electronic and electrical appliances.

The country's foreign reserves are currently at $4 billion (£2.8bn), down from $7.8bn (£5.6bn) in late 2019 when the government of president Gotabaya Rajapaksa came to power promising robust growth.

The economy shrank by a record 3.6 per cent last year - the worst downturn since independence from Britain in 1948 - as the pandemic wiped out the island's lucrative tourism sector.

Lakshman said Sri Lanka would continue to meet its debt service obligations amounting to $3.6bn (£2.5bn) in the next six months.

Sri Lanka has loaned $250 million (£179m) from neighbouring Bangladesh, which is expected to come through next month.

It also expects to borrow another $400m (£287m) from India in August.

The country also hopes to get $800m (£575m) from the International Monetary Fund in August, the governor said.

In May, Sri Lanka secured a $500m (£359m) loan from South Korea.

China's central bank also granted a $1.5bn (£1bn) currency swap to finance imports from the Asian giant in February.

Sri Lanka has borrowed heavily over the years. Some of the debt was used to finance vanity projects like massive convention centres and other infrastructure that have become white elephants.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less